ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.47
+0.18 (+1.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close13.29
Open13.36
Bid11.01 x 900
Ask13.65 x 800
Day's Range13.36 - 13.61
52 Week Range10.21 - 23.64
Volume217,457
Avg. Volume324,137
Market Cap742.663M
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-2.82
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.13
  • TheStreet.com5 days ago

    2 Biotech Names See Directors Direct Cash to Their Shares

    The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of ITCI earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 Intra-Cellular Therapies Inc Earnings Call

  • GlobeNewswire9 days ago

    Intra-Cellular Therapies to Present at 2019 RBC Capital Markets Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2019 RBC Capital Markets Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire10 days ago

    Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced the presentation of posters highlighting the lumateperone program in schizophrenia at the 2019 American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18-22, 2019. Lumateperone is a novel investigational drug currently under review by the FDA as a potential treatment for adults with schizophrenia.

  • Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57%
    Simply Wall St.15 days ago

    Such Is Life: How Intra-Cellular Therapies (NASDAQ:ITCI) Shareholders Saw Their Shares Drop 57%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)
    Insider Monkey17 days ago

    Here’s What Hedge Funds Think About Intra-Cellular Therapies Inc (ITCI)

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript
    Motley Fool17 days ago

    Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript

    ITCI earnings call for the period ending March 31, 2019.

  • Associated Press17 days ago

    Intra-Cellular: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 63 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswire17 days ago

    Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update

    NEW YORK, May 08, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS).

  • GlobeNewswire23 days ago

    Intra-Cellular Therapies to Host First Quarter 2019 Financial Results Conference Call and Webcast

    Intra-Cellular Therapies, Inc. (ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, May 8, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2019. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
    Zacks26 days ago

    Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?

    Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

  • GlobeNewswirelast month

    Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel Laureate whose pioneering research revolutionized our understanding of the biochemistry of the brain. Dr. Greengard’s Nobel prize-winning work in intracellular signaling was the foundation of the company’s formation in 2002. “We are deeply saddened by the news of Paul’s passing.

  • GlobeNewswirelast month

    Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced additional results from its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone, an investigational drug, in patients with stable symptoms of schizophrenia. Results were also presented on the improvements in symptoms of depression in patients with moderate to severe co-morbid depression.  The data were presented at the 2019 Congress of the Schizophrenia International Research Society (SIRS), which was held in Orlando, Florida, April 10-14, 2019. “Schizophrenia is a multidimensional illness with high rates of comorbidities, including depressive symptoms.

  • Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
    Simply Wall St.2 months ago

    Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you love investing in stocks you're bound to buy some losers. Long term Intra-Cellular Therapies, Inc. (NASDAQ:ITCI...

  • GlobeNewswire2 months ago

    Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of John A. Bardi as Senior Vice President for Market Access, Policy and Government Affairs.  Mr. Bardi has over 30 years of biopharmaceutical and health system industry experience with a strong track record of innovation and building high-performing Market Access, Government Affairs, and Digital Medicine business development teams and capabilities across many disease areas.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 39th Annual Healthcare Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT

    Q4 2018 Intra-Cellular Therapies Inc Earnings Call

  • Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript

    ITCI earnings call for the period ending December 31, 2018.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

    NEW YORK, Feb. 27, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, February 27, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire3 months ago

    Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
    Investor's Business Daily3 months ago

    Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst

    An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.

  • Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
    Simply Wall St.4 months ago

    Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...

  • ACCESSWIRE5 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI

    NEW YORK, NY / ACCESSWIRE / January 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 18, 2018, Intra-Cellular Therapies issued a press release announcing that "an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company's ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimer's disease (Study 201)." Intra-Cellular Therapies stated that "[t]he DMC concluded that Study 201 is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility.